TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The LIFE Study - Lifestyle Interventions and Independence for Elders
Brief Summary: Based upon promising results from a pilot study among 424 sedentary older adults who were randomized to a physical activity intervention or a successful aging health education intervention, a Phase 3 multi-center randomized controlled trial is being conducted to compare a moderate-intensity physical activity program to a successful aging health education program in 1,600 sedentary older adults who are followed for an average of 2.7 years.

The primary aim was to assess the long-term effects of the proposed interventions on the primary outcome of major mobility disability, defined as inability to walk 400 m.


Options:
A: Arm Label: Meditation; Type: EXPERIMENTAL; Interventions: Behavioral: Meditation | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Waiting list control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Meditation; Assigned to Arm(s): Meditation | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
B: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Standardized Rehabilitation; Type: OTHER; Interventions: Other: Standardized Rehabilitation | Intervention Type: OTHER; Name: Standardized Rehabilitation; Assigned to Arm(s): Standardized Rehabilitation | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Physical Activity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical Activity | Arm Label: Successful Aging; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Successful Aging | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Physical Activity | Intervention Type: BEHAVIORAL; Name: Successful Aging; Assigned to Arm(s): Successful Aging
D: Arm Label: Physiotherapy+conventional treatment; Type: EXPERIMENTAL; Interventions: Other: Physiotherapy+conventional treatment | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conventional treatment | Intervention Type: OTHER; Name: Physiotherapy+conventional treatment; Assigned to Arm(s): Physiotherapy+conventional treatment | Intervention Type: DRUG; Name: Conventional treatment; Assigned to Arm(s): Conventional treatment

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The LIFE Study - Lifestyle Interventions and Independence for Elders
Brief Summary: Based upon promising results from a pilot study among 424 sedentary older adults who were randomized to a physical activity intervention or a successful aging health education intervention, a Phase 3 multi-center randomized controlled trial is being conducted to compare a moderate-intensity physical activity program to a successful aging health education program in 1,600 sedentary older adults who are followed for an average of 2.7 years.

The primary aim was to assess the long-term effects of the proposed interventions on the primary outcome of major mobility disability, defined as inability to walk 400 m.


Options:
A: Arm Label: Exercise and advise to stay active; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Arm Label: Rest and use of flexible lumbar belt; Type: EXPERIMENTAL; Interventions: Other: Restitution | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise and advise to stay active | Intervention Type: OTHER; Name: Restitution; Assigned to Arm(s): Rest and use of flexible lumbar belt
B: Arm Label: Spinal orthosis group; Type: ACTIVE_COMPARATOR; Interventions: Device: Spinal orthosis Spinomed | Arm Label: Equipment training group; Type: ACTIVE_COMPARATOR; Interventions: Other: Equipment training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Spinal orthosis Spinomed; Assigned to Arm(s): Spinal orthosis group | Intervention Type: OTHER; Name: Equipment training; Assigned to Arm(s): Equipment training group
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Intervention
D: Arm Label: Physical Activity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical Activity | Arm Label: Successful Aging; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Successful Aging | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Physical Activity | Intervention Type: BEHAVIORAL; Name: Successful Aging; Assigned to Arm(s): Successful Aging

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Palivizumab Treatment on Subsequent Recurrent Wheezing in Preterm Infants: Case-control Study by Scientific Committee of Recurrent Wheezing (SCREW)
Brief Summary: The hypothesis of the present study is that the prophylaxis with palivizumab to prevent the severe RS virus infection during the infancy among preterm infants may reduce the risk of subsequent recurrent wheezing in childhood.

The infants born between July 1st and December 31st in 2007 with the gestational age between 33 and 35 weeks were enrolled into the study at the end of RS virus infection season, April 2008. The infants were unintentionally divided into two groups, either palivizumab treated or untreated group at the enrollment, because the timing for palivizumab prophylaxis were already ended.

The study infants will be followed up until the age of 3 with recording the incidence of either parent reported or physician diagnosed recurrent wheezing.

The difference of the incidence of the recurrent wheezing between the groups will be analyzed with Kaplan-Meier method.


Options:
A: Arm Label: Treated; Type: N/A; Interventions: N/A | Arm Label: Untreated; Type: N/A; Interventions: N/A
B: Arm Label: Palivizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Palivizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Palivizumab; Assigned to Arm(s): Palivizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Motavizumab followed by Palivizumab; Type: EXPERIMENTAL; Interventions: Biological: Motavizumab, palivizumab | Arm Label: Palivizumab followed by motavizumab; Type: EXPERIMENTAL; Interventions: Biological: Palivizumab, motavizumab | Arm Label: Motavizumab control; Type: EXPERIMENTAL; Interventions: Biological: Motavizumab | Intervention Type: BIOLOGICAL; Name: Motavizumab, palivizumab; Assigned to Arm(s): Motavizumab followed by Palivizumab | Intervention Type: BIOLOGICAL; Name: Palivizumab, motavizumab; Assigned to Arm(s): Palivizumab followed by motavizumab | Intervention Type: BIOLOGICAL; Name: Motavizumab; Assigned to Arm(s): Motavizumab control
D: Arm Label: Treated; Type: N/A; Interventions: N/A | Arm Label: Untreated; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Palivizumab Treatment on Subsequent Recurrent Wheezing in Preterm Infants: Case-control Study by Scientific Committee of Recurrent Wheezing (SCREW)
Brief Summary: The hypothesis of the present study is that the prophylaxis with palivizumab to prevent the severe RS virus infection during the infancy among preterm infants may reduce the risk of subsequent recurrent wheezing in childhood.

The infants born between July 1st and December 31st in 2007 with the gestational age between 33 and 35 weeks were enrolled into the study at the end of RS virus infection season, April 2008. The infants were unintentionally divided into two groups, either palivizumab treated or untreated group at the enrollment, because the timing for palivizumab prophylaxis were already ended.

The study infants will be followed up until the age of 3 with recording the incidence of either parent reported or physician diagnosed recurrent wheezing.

The difference of the incidence of the recurrent wheezing between the groups will be analyzed with Kaplan-Meier method.


Options:
A: Arm Label: Treated; Type: N/A; Interventions: N/A | Arm Label: Untreated; Type: N/A; Interventions: N/A
B: Intervention Type: DRUG; Name: Amoxycillin; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Motavizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Motavizumab | Intervention Type: BIOLOGICAL; Name: Motavizumab; Assigned to Arm(s): Motavizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Experimental; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxicillin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Amoxicillin; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Effect of Ambrisentan on Digital Microvascular Flow in Patients With Systemic Sclerosis Using Laser Doppler Perfusion Imaging
Brief Summary: The purpose of this study is to investigate the effectiveness of a drug called ambrisentan, approved by the FDA for use in pulmonary hypertension (a condition where there is increased pressure in the right side of the heart) in scleroderma patients, to see if this medicine may be beneficial in relieving and/or preventing Raynaud's flares in you and other patients like you. This medicine may have some short-term and long-term benefits in persons with scleroderma


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): N/A
C: Arm Label: ambrisentan; Type: ACTIVE_COMPARATOR; Interventions: Drug: ambrisentan | Arm Label: sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: ambrisentan | Intervention Type: DRUG; Name: ambrisentan; Assigned to Arm(s): ambrisentan, sugar pill
D: Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Effect of Ambrisentan on Digital Microvascular Flow in Patients With Systemic Sclerosis Using Laser Doppler Perfusion Imaging
Brief Summary: The purpose of this study is to investigate the effectiveness of a drug called ambrisentan, approved by the FDA for use in pulmonary hypertension (a condition where there is increased pressure in the right side of the heart) in scleroderma patients, to see if this medicine may be beneficial in relieving and/or preventing Raynaud's flares in you and other patients like you. This medicine may have some short-term and long-term benefits in persons with scleroderma


Options:
A: Arm Label: Ambrisentan; Type: EXPERIMENTAL; Interventions: Drug: ambrisentan | Intervention Type: DRUG; Name: ambrisentan; Assigned to Arm(s): Ambrisentan
B: Arm Label: Bosentan; Type: EXPERIMENTAL; Interventions: Drug: Bosentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: ambrisentan; Type: ACTIVE_COMPARATOR; Interventions: Drug: ambrisentan | Arm Label: sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: ambrisentan | Intervention Type: DRUG; Name: ambrisentan; Assigned to Arm(s): ambrisentan, sugar pill
D: Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of an Emergency Obstetric and Neonatal Care (EmONC) Intervention Package to Reduce Adverse Pregnancy Outcomes in Low Resource Settings (The EmONC Trial)
Brief Summary: The objective of this cluster randomized controlled trial is to reduce maternal and neonatal mortality by increasing access to and improving the quality of obstetric and neonatal care for pregnant women in study clusters. It is hypothesized that a 25% reduction in \>28 week or \>1000 gram stillbirth and 7-day neonatal mortality will be achieved in the intervention clusters by a multifaceted Emergency Obstetric Neonatal Care (EmONC) package that will be introduced by an EmONC team.


Options:
A: Arm Label: Intervention Kangaroo Mother Care; Type: EXPERIMENTAL; Interventions: Behavioral: Kangaroo Mother Care | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Kangaroo Mother Care; Assigned to Arm(s): Intervention Kangaroo Mother Care
B: Arm Label: EMONC: Community mobilization, HBLSS and Facility Improvement; Type: EXPERIMENTAL; Interventions: Behavioral: Community Mobilization, HBLSS and facility improvement | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Community Mobilization, HBLSS and facility improvement; Assigned to Arm(s): EMONC: Community mobilization, HBLSS and Facility Improvement
C: Intervention Type: BEHAVIORAL; Name: Improved management of severe neonatal infections; Assigned to Arm(s): N/A
D: Arm Label: Individual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: CenteringPregnancy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CenteringPregnancy | Arm Label: CenteringPregnancyPlus; Type: EXPERIMENTAL; Interventions: Behavioral: CenteringPregnancy, Behavioral: CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: CenteringPregnancy; Assigned to Arm(s): CenteringPregnancy, CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: CenteringPregnancyPlus; Assigned to Arm(s): CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Individual Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of an Emergency Obstetric and Neonatal Care (EmONC) Intervention Package to Reduce Adverse Pregnancy Outcomes in Low Resource Settings (The EmONC Trial)
Brief Summary: The objective of this cluster randomized controlled trial is to reduce maternal and neonatal mortality by increasing access to and improving the quality of obstetric and neonatal care for pregnant women in study clusters. It is hypothesized that a 25% reduction in \>28 week or \>1000 gram stillbirth and 7-day neonatal mortality will be achieved in the intervention clusters by a multifaceted Emergency Obstetric Neonatal Care (EmONC) package that will be introduced by an EmONC team.


Options:
A: Intervention Type: DRUG; Name: Co-Trimoxazole; TMP-SMZ; Assigned to Arm(s): N/A
B: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention
C: Arm Label: EmONC package; Type: EXPERIMENTAL; Interventions: Behavioral: EmONC package | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: EmONC package; Assigned to Arm(s): EmONC package
D: Arm Label: EMONC: Community mobilization, HBLSS and Facility Improvement; Type: EXPERIMENTAL; Interventions: Behavioral: Community Mobilization, HBLSS and facility improvement | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Community Mobilization, HBLSS and facility improvement; Assigned to Arm(s): EMONC: Community mobilization, HBLSS and Facility Improvement

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Pregabalin in the Management of Chronic Uremic Pruritus
Brief Summary: Uraemic pruritus (UP) remains a frequent and distressing problem in patients with advanced or end-stage renal disease. Its intensity ranges from sporadic discomfort to complete restlessness during both the day- and night-time and its distribution varies significantly over time. Many attempts have been made to relieve this bothersome symptom in affected patients, however with generally limited success. Incidence of UP varies widely between studies and seems to decline over the last 30 years (from 85% in the 1970s and 50-60% in the 1980s to a 22% in the 2000s) (Gunal AI).

We use Pregabalin for the relief of diabetic neuropathic pain in patients on haemodialysis in our centre. In addition to neuropathic pain, several of our patients have complained of pruritus and after Pregabalin treatment, their pruritus has promptly and completely resolved. Accordingly, we intend to conduct a double-blind, placebo-controlled, crossover trial to assess the effectiveness of Pregabalin in chronic UP.


Options:
A: Arm Label: nalbuphine HCl ER 60mg; Type: EXPERIMENTAL; Interventions: Drug: nalbuphine HCl ER tablets 60 mg BID | Arm Label: nalbuphine HCl ER 120mg; Type: EXPERIMENTAL; Interventions: Drug: nalbuphine HCl ER tablets 120mg BID | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablets BID | Intervention Type: DRUG; Name: nalbuphine HCl ER tablets 60 mg BID; Assigned to Arm(s): nalbuphine HCl ER 60mg | Intervention Type: DRUG; Name: nalbuphine HCl ER tablets 120mg BID; Assigned to Arm(s): nalbuphine HCl ER 120mg | Intervention Type: DRUG; Name: Placebo tablets BID; Assigned to Arm(s): Sugar pill
B: Arm Label: Wheat; Type: PLACEBO_COMPARATOR; Interventions: Drug: Wheat | Arm Label: Fumaria; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaria | Intervention Type: DRUG; Name: Wheat; Assigned to Arm(s): Wheat | Intervention Type: DRUG; Name: Fumaria; Assigned to Arm(s): Fumaria
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjuvant Treatment of Resectable Cholangiocellular Carcinoma (CCC) With Cisplatin Plus Gemcitabine. A Prospective Single Center Phase Ib-II Study.
Brief Summary: OBJECTIVES

Primary objective:

The primary objective of the trial is to determine the safety of adjuvant treatment with cisplatin plus gemcitabine for a period of 6 months after curative resection of cholangiocellular carcinoma

Secondary objectives:

Secondary objectives of the trial are to assess the feasibility and efficacy of the adjuvant therapy and to determine duration of response and patterns of failure compared to historical controls without postoperative treatment

Exploratory objectives:

To obtain blood samples and tumor tissue after resection for establishment and characterization of new cholangiocarcinoma cell lines and tumor antigens. Other aims are identification of tumor specific antibodies from blood samples, and characterization of tumor antigens with consecutive development of new specific immunological therapies, e.g. cancer-testis antigens (CTA) for tumor vaccination.

* Trial with medicinal product


Options:
A: Arm Label: Cisplatin plus Gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin and Gemcitabine | Intervention Type: DRUG; Name: Cisplatin and Gemcitabine; Assigned to Arm(s): Cisplatin plus Gemcitabine
B: Arm Label: Test Group; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine, Drug: Apatinib | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Control Group, Test Group | Intervention Type: DRUG; Name: Apatinib; Assigned to Arm(s): Test Group
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Radiation: Concurrent Chemoradiotherapy, Drug: capecitabine, Drug: gemcitabine | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: capecitabine, Drug: gemcitabine | Intervention Type: RADIATION; Name: Concurrent Chemoradiotherapy; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): Arm 1, Arm 2
D: Arm Label: Gemcitabine plus Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine, Drug: Cisplatin | Arm Label: Capecitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine plus Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Gemcitabine plus Cisplatin | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Capecitabine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) Following a Two-Week Washout Period
Brief Summary: This is a research study for people with high blood phosphorus levels who are on dialysis. This medical condition can cause weakening of the bones and damage other organs. This can lead to many health problems, and sometimes death. Phosphorus is in much of the food we eat, and is helpful to us in small amounts. Patients with kidney failure have trouble getting rid of the phosphorus eaten in food. Dialysis can help remove some of the phosphorus, but often patients must take a phosphate binder like PhosLo®, Renagel®, or Renvela® to bring the blood phosphorus levels back to normal. The purpose of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a phosphate binder.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: sevelamer phosphate-binders | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Calcium Carbonate | Intervention Type: DRUG; Name: sevelamer phosphate-binders; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Calcium Carbonate; Assigned to Arm(s): 2
B: Arm Label: 1 g/day; Type: EXPERIMENTAL; Interventions: Drug: ferric citrate | Arm Label: 6 g/day; Type: EXPERIMENTAL; Interventions: Drug: ferric citrate | Arm Label: 8 g/day; Type: EXPERIMENTAL; Interventions: Drug: ferric citrate | Intervention Type: DRUG; Name: ferric citrate; Assigned to Arm(s): 1 g/day, 6 g/day, 8 g/day
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Lanthanum carbonate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lanthanum carbonate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Sevelamer hydrochloride; Assigned to Arm(s): N/A

Answer: B